BAP1 and mesothelioma: In view of the clinical availability of the inhibitors used against EZH2 (tazemetostat) and FGFR (AZD4547), this highly synergistic combination is worth testing as a therapeutic regimen against mesothelioma and potentially other BAP1-mutated malignancies as well.